India, Oct. 1 -- With Ozempic now approved in India for type 2 diabetes management, the conversation around glucagon-like peptide-1 (GLP-1) therapies has gained momentum. According to medical experts, the launch of these diabetes management drugs in the world's 'diabetes capital' can be a significant step in controlling the rising burden of type 2 diabetes and obesity, albeit with caution. While both Ozempic (Semaglutide) and Mounjaro (Tirzepatide) serve a common purpose of controlling blood sugar levels and even supporting weight loss, they differ significantly in how they work, their potential side effects profiles, and who they are best suited for.

In a latest development, India's drug regulatory authority, the Central Drugs Standard ...